Equity Profile

RMD

ResMed Inc.

Health CareHealth Care Equipment$28.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ4-2026After Close5:00 PM EDT

Company Snapshot

ResMed Inc. is a health care company focused on developing equipment related to sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability, and investors will be looking for continued growth in this area.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and meet increasing demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

ResMed Inc. is a health care company focused on developing equipment related to sleep apnea and chronic obstructive pulmonary disease (COPD). With a market cap of $29 billion, it plays a crucial role in the health care equipment sector, especially as demand for respiratory care solutions continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q3-2026, ResMed reported an EPS of $2.86, beating estimates by 2.58%. The stock saw a slight increase of 0.89% the following day, indicating a positive market reaction.

Management Promises & Guidance

Continued focus on innovation in respiratory care solutions.
Commitment to expanding market presence in emerging markets.
Efforts to enhance customer service and support.

Expectations

Wall Street Expectations

Overall expectations for ResMed's upcoming earnings are cautiously optimistic, given its strong track record of beating EPS estimates.

Bull Case

If ResMed continues its trend of exceeding EPS expectations, it could signal robust demand for its products and strong operational efficiency.

Bear Case

Conversely, any signs of slowing revenue growth or increased competition could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q4-2026?

Given ResMed's history of beating EPS estimates, the market will closely watch this number to gauge ongoing profitability.

How is revenue growth trending in key markets?

Understanding revenue growth will provide insight into the company's market position and demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate ResMed's ability to maintain its growth trajectory, especially in emerging markets where demand for respiratory care is rising.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational performance.

Options pricing suggests a significant move, which may reflect investor sentiment that is not fully captured in consensus estimates.

Key Risk

If revenue growth in key markets comes in below expectations, it could challenge the bullish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around ResMed's ability to maintain its growth trajectory in a competitive health care market.

Bull Confirmed If

An EPS of $2.90 or higher would confirm the bull case, indicating strong demand and operational efficiency.

Bear Confirmed If

An EPS below $2.70 could confirm the bear case, suggesting potential issues with revenue growth or market competition.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests a potential stock increase of around +0.21%, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may react mildly, reflecting market caution.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around -0.54%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in respiratory care.
2Insights into market expansion strategies, particularly in emerging markets.
3Management's commentary on competitive pressures and pricing strategies.
4Details on customer satisfaction and support initiatives.
5Any changes in guidance or outlook for the upcoming fiscal year.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

ResMed Inc. is a health care company focused on developing equipment related to sleep apnea and chronic obstructive pulmonary disease (COPD)....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability, and investors will be looking for continued growth in this area.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and meet increasing demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

RMD Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+3.72%

Avg Stock Reaction

+0.21%

Last Quarter Recap

In Q3-2026, ResMed reported an EPS of $2.86, beating estimates by 2.58%. The stock saw a slight increase of 0.89% the following day, indicating a positive market reaction.

Management Promises & Guidance

Continued focus on innovation in respiratory care solutions.
Commitment to expanding market presence in emerging markets.
Efforts to enhance customer service and support.

Expectations

Wall Street Expectations

Overall expectations for ResMed's upcoming earnings are cautiously optimistic, given its strong track record of beating EPS estimates.

Bull Case

If ResMed continues its trend of exceeding EPS expectations, it could signal robust demand for its products and strong operational efficiency.

Bear Case

Conversely, any signs of slowing revenue growth or increased competition could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q4-2026?

Given ResMed's history of beating EPS estimates, the market will closely watch this number to gauge ongoing profitability.

How is revenue growth trending in key markets?

Understanding revenue growth will provide insight into the company's market position and demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate ResMed's ability to maintain its growth trajectory, especially in emerging markets where demand for respiratory care is rising.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational performance.

Options pricing suggests a significant move, which may reflect investor sentiment that is not fully captured in consensus estimates.

Key Risk

If revenue growth in key markets comes in below expectations, it could challenge the bullish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around ResMed's ability to maintain its growth trajectory in a competitive health care market.

Bull Confirmed If

An EPS of $2.90 or higher would confirm the bull case, indicating strong demand and operational efficiency.

Bear Confirmed If

An EPS below $2.70 could confirm the bear case, suggesting potential issues with revenue growth or market competition.

Pre-Earnings Positioning

Options Market

Implied Move

±5.12%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings announcement.

Options are pricing ±5.1% while RMD has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

31.1%

Calls (4K)P/C Ratio: 0.65Puts (155K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ResMed beats expectations, history suggests a potential stock increase of around +0.21%, confirming strong demand.

In-Line / Cautious

If results are in line with expectations, the stock may react mildly, reflecting market caution.

Miss

A miss could lead to a decline, with historical patterns suggesting a potential drop of around -0.54%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in respiratory care.
2Insights into market expansion strategies, particularly in emerging markets.
3Management's commentary on competitive pressures and pricing strategies.
4Details on customer satisfaction and support initiatives.
5Any changes in guidance or outlook for the upcoming fiscal year.